{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:56:06Z","timestamp":1780372566184,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.atherosclerosis.2016.06.015","type":"journal-article","created":{"date-parts":[[2016,6,12]],"date-time":"2016-06-12T03:10:34Z","timestamp":1465701034000},"page":"119-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol"],"prefix":"10.1016","volume":"251","author":[{"given":"Knut Tore","family":"Lappeg\u00e5rd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terje","family":"Enebakk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Thunhaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Hovland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib1","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia a scientific statement from the american heart association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/CIRCRESAHA.115.306297","article-title":"The success story of LDL cholesterol lowering","volume":"118","author":"Pedersen","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib3","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ecl.2015.09.003","article-title":"Lipoprotein apheresis","volume":"45","author":"Moriarty","year":"2016","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.transci.2011.11.016","article-title":"Three different LDL apheresis columns efficiently and equally reduce lipoprotein(a) concentrations in patients with familial hypercholesterolemia and small apolipoprotein(a) particles","volume":"46","author":"Hovland","year":"2012","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib6","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib7","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2217\/clp.11.52","article-title":"Side effects in low-density lipoprotein apheresis - types, frequency and clinical relevance","volume":"6","author":"Lappeg\u00e5rd","year":"2011","journal-title":"Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11883-014-0465-6","article-title":"Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances","volume":"17","author":"Stefanutti","year":"2015","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib9","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1093\/eurheartj\/ehv174","article-title":"PCSK9 (Proprotein convertase subtilisin\/kexin type 9) inhibitors: past, present, and the future","volume":"36","author":"Shimada","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.atherosclerosis.2014.12.017","article-title":"On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects","volume":"238","author":"Tavori","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2016.02.018","article-title":"Targeting PCSK9 for therapeutic gains: have we addressed all the concerns?","volume":"248","author":"Banerjee","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib12","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib13","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2013a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/jca.20223","article-title":"Different inflammatory responses induced by three LDL-lowering apheresis columns","volume":"24","author":"Hovland","year":"2009","journal-title":"J.\u00a0Clin. Apher."},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.atherosclerosis.2009.06.010","article-title":"Efficacy criteria and cholesterol targets for LDL apheresis","volume":"208","author":"Thompson","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib17","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A\u00a0proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","article-title":"Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-Week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial","volume":"129","author":"Koren","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib19","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MOL.0b013e328353ef07","article-title":"Reverse cholesterol transport in familial hypercholesterolemia","volume":"23","author":"Guerin","year":"2012","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.atherosclerosis.2015.08.027","article-title":"HDL: quality or quantity?","volume":"243","author":"Santos-Gallego","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s11883-011-0177-0","article-title":"Experimental models for the investigation of high-density lipoprotein-mediated cholesterol efflux","volume":"3","author":"Santos-Gallego","year":"2011","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib24","first-page":"229","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat. Clin. Pract. Cardiovasc Med."},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib25","doi-asserted-by":"crossref","DOI":"10.1194\/jlr.R056549","article-title":"Lipoprotein apheresis to treat elevated lipoprotein (a)","author":"Waldmann","year":"2016","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib26","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","article-title":"The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis","volume":"37","author":"Lipinski","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(02)00251-4","article-title":"LDL apheresis","volume":"167","author":"Thompson","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib28","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.metabol.2012.07.024","article-title":"Lipoprotein(a) metabolism: potential sites for therapeutic targets","volume":"62","author":"Hoover-Plow","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib29","first-page":"467","article-title":"Selective whole blood lipoprotein apheresis to prevent pancreatitis in drug refractory hypertriglyceridemia","volume":"11","author":"Hovland","year":"2010","journal-title":"JOP"},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2796.2010.02333.x","article-title":"Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up","volume":"270","author":"Langsted","year":"2011","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib32","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/eurheartj\/ehu500","article-title":"Triglycerides on the rise: should we swap seats on the seesaw?","volume":"36","author":"Libby","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2016.06.015_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/nrcardio.2015.92","article-title":"Management of patients with familial hypercholesterolaemia","author":"Reiner","year":"2015","journal-title":"Nat. Rev. Cardiol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191501630260X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191501630260X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T21:57:05Z","timestamp":1617487025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002191501630260X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":33,"alternative-id":["S002191501630260X"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.06.015","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}